Skip to main content

Waldenstrom Macroglobulinemia clinical trials at UCSD
3 in progress, 2 open to eligible people

  • A Long-term Extension Study of PCI-32765 (Ibrutinib)

    open to eligible people ages 18 years and up

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are currently enrolled in PCI-32765 studies that have been completed according to the parent protocol, are actively receiving treatment with PCI-32765, and who continue to benefit from PCI-32765 treatment.

    La Jolla, California and other locations

  • Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

    open to eligible people ages 18 years and up

    This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.

    San Diego, California and other locations

  • A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

    Sorry, in progress, not accepting new patients

    This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

    La Jolla, California and other locations

Last updated: